As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...

But starting a GLP-1 isn't just about picking up a prescription and hoping for the best. These medications work by mimicking a hormone that targets areas of the brain that regulate appetite and food ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

On the heels of STRIDE, one of the first trials to show glucagon-like peptide-1 (GLP-1) receptor agonists can help patients with PAD, a retrospective study of more than 100,000 patients provides more ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...

Our work continues on behalf of TRICARE For Life beneficiaries. Learn the latest, and find out how to share your story with ...

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...